Zhejiang Medicine Co Ltd (600216) - Net Assets
Based on the latest financial reports, Zhejiang Medicine Co Ltd (600216) has net assets worth CN¥11.37 Billion CNY (≈ $1.66 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥14.18 Billion ≈ $2.07 Billion USD) and total liabilities (CN¥2.81 Billion ≈ $411.69 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 600216 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥11.37 Billion |
| % of Total Assets | 80.16% |
| Annual Growth Rate | 13.7% |
| 5-Year Change | 20.77% |
| 10-Year Change | 58.6% |
| Growth Volatility | 25.6 |
Zhejiang Medicine Co Ltd - Net Assets Trend (1997–2025)
This chart illustrates how Zhejiang Medicine Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 600216 market cap.
Annual Net Assets for Zhejiang Medicine Co Ltd (1997–2025)
The table below shows the annual net assets of Zhejiang Medicine Co Ltd from 1997 to 2025. Also explore Zhejiang Medicine Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥11.09 Billion ≈ $1.62 Billion |
+2.03% |
| 2024-12-31 | CN¥10.87 Billion ≈ $1.59 Billion |
+8.83% |
| 2023-12-31 | CN¥9.99 Billion ≈ $1.46 Billion |
+2.85% |
| 2022-12-31 | CN¥9.71 Billion ≈ $1.42 Billion |
+5.75% |
| 2021-12-31 | CN¥9.18 Billion ≈ $1.34 Billion |
+14.35% |
| 2020-12-31 | CN¥8.03 Billion ≈ $1.18 Billion |
-2.69% |
| 2019-12-31 | CN¥8.25 Billion ≈ $1.21 Billion |
+2.08% |
| 2018-12-31 | CN¥8.08 Billion ≈ $1.18 Billion |
+3.92% |
| 2017-12-31 | CN¥7.78 Billion ≈ $1.14 Billion |
+11.26% |
| 2016-12-31 | CN¥6.99 Billion ≈ $1.02 Billion |
+5.69% |
| 2015-12-31 | CN¥6.62 Billion ≈ $968.00 Million |
+0.81% |
| 2014-12-31 | CN¥6.56 Billion ≈ $960.18 Million |
+1.25% |
| 2013-12-31 | CN¥6.48 Billion ≈ $948.29 Million |
+4.57% |
| 2012-12-31 | CN¥6.20 Billion ≈ $906.81 Million |
+40.83% |
| 2011-12-31 | CN¥4.40 Billion ≈ $643.92 Million |
+13.90% |
| 2010-12-31 | CN¥3.86 Billion ≈ $565.33 Million |
+35.02% |
| 2009-12-31 | CN¥2.86 Billion ≈ $418.70 Million |
+57.89% |
| 2008-12-31 | CN¥1.81 Billion ≈ $265.19 Million |
+107.42% |
| 2007-12-31 | CN¥873.73 Million ≈ $127.85 Million |
+12.40% |
| 2006-12-31 | CN¥777.31 Million ≈ $113.74 Million |
+6.16% |
| 2005-12-31 | CN¥732.23 Million ≈ $107.15 Million |
+13.40% |
| 2004-12-31 | CN¥645.68 Million ≈ $94.48 Million |
+2.74% |
| 2003-12-31 | CN¥628.48 Million ≈ $91.97 Million |
-0.20% |
| 2002-12-31 | CN¥629.71 Million ≈ $92.15 Million |
+3.49% |
| 2001-12-31 | CN¥608.50 Million ≈ $89.04 Million |
-4.18% |
| 2000-12-31 | CN¥635.03 Million ≈ $92.92 Million |
+1.59% |
| 1999-12-31 | CN¥625.07 Million ≈ $91.47 Million |
+79.30% |
| 1998-12-31 | CN¥348.61 Million ≈ $51.01 Million |
+14.61% |
| 1997-12-31 | CN¥304.17 Million ≈ $44.51 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Medicine Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 22819.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥6.36 Billion | 58.15% |
| Other Components | CN¥4.58 Billion | 41.85% |
| Total Equity | CN¥10.94 Billion | 100.00% |
Zhejiang Medicine Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Medicine Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dime Community Bancshares, Inc.
NYSE:DCOM
|
$1.79 Billion |
|
OVH Groupe SAS
PA:OVH
|
$1.79 Billion |
|
Zydus Wellness Limited
NSE:ZYDUSWELL
|
$1.79 Billion |
|
Tianjin Port Co Ltd
SHG:600717
|
$1.79 Billion |
|
Zymeworks Inc. Common Stock
NASDAQ:ZYME
|
$1.79 Billion |
|
Woolworths Holdings Ltd
JSE:WHL
|
$1.79 Billion |
|
Guangdong Rongtai Industry Co Ltd
SHG:600589
|
$1.79 Billion |
|
National Bank Holdings Corporation
NYSE:NBHC
|
$1.79 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Medicine Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 10,648,142,085 to 10,943,373,741, a change of 295,231,656 (2.8%).
- Net income of 873,380,229 contributed positively to equity growth.
- Dividend payments of 376,692,920 reduced retained earnings.
- Other comprehensive income decreased equity by 2,696,089,239.
- Other factors increased equity by 2,494,633,586.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥873.38 Million | +7.98% |
| Dividends Paid | CN¥376.69 Million | -3.44% |
| Other Comprehensive Income | CN¥-2.70 Billion | -24.64% |
| Other Changes | CN¥2.49 Billion | +22.8% |
| Total Change | CN¥- | 2.77% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Medicine Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.12x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 33.75x to 1.12x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-12-31 | CN¥0.38 | CN¥12.72 | x |
| 1998-12-31 | CN¥0.43 | CN¥12.72 | x |
| 1999-12-31 | CN¥0.77 | CN¥12.72 | x |
| 2000-12-31 | CN¥0.79 | CN¥12.72 | x |
| 2001-12-31 | CN¥0.75 | CN¥12.72 | x |
| 2002-12-31 | CN¥0.77 | CN¥12.72 | x |
| 2003-12-31 | CN¥0.78 | CN¥12.72 | x |
| 2004-12-31 | CN¥0.80 | CN¥12.72 | x |
| 2005-12-31 | CN¥0.90 | CN¥12.72 | x |
| 2006-12-31 | CN¥0.95 | CN¥12.72 | x |
| 2007-12-31 | CN¥1.11 | CN¥12.72 | x |
| 2008-12-31 | CN¥2.22 | CN¥12.72 | x |
| 2009-12-31 | CN¥3.52 | CN¥12.72 | x |
| 2010-12-31 | CN¥4.75 | CN¥12.72 | x |
| 2011-12-31 | CN¥5.42 | CN¥12.72 | x |
| 2012-12-31 | CN¥7.29 | CN¥12.72 | x |
| 2013-12-31 | CN¥6.86 | CN¥12.72 | x |
| 2014-12-31 | CN¥6.93 | CN¥12.72 | x |
| 2015-12-31 | CN¥6.93 | CN¥12.72 | x |
| 2016-12-31 | CN¥7.44 | CN¥12.72 | x |
| 2017-12-31 | CN¥7.77 | CN¥12.72 | x |
| 2018-12-31 | CN¥7.97 | CN¥12.72 | x |
| 2019-12-31 | CN¥8.20 | CN¥12.72 | x |
| 2020-12-31 | CN¥8.01 | CN¥12.72 | x |
| 2021-12-31 | CN¥9.16 | CN¥12.72 | x |
| 2022-12-31 | CN¥9.66 | CN¥12.72 | x |
| 2023-12-31 | CN¥10.09 | CN¥12.72 | x |
| 2024-12-31 | CN¥11.10 | CN¥12.72 | x |
| 2025-12-31 | CN¥11.38 | CN¥12.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Medicine Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.98%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.83%
- • Asset Turnover: 0.63x
- • Equity Multiplier: 1.29x
- Recent ROE (7.98%) is below the historical average (10.62%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | 12.22% | 4.05% | 0.97x | 3.12x | CN¥6.73 Million |
| 1998 | 10.45% | 3.27% | 0.97x | 3.30x | CN¥1.53 Million |
| 1999 | 5.36% | 2.80% | 0.69x | 2.78x | CN¥-28.75 Million |
| 2000 | 1.29% | 0.76% | 0.75x | 2.27x | CN¥-55.19 Million |
| 2001 | 2.73% | 1.89% | 0.55x | 2.61x | CN¥-43.61 Million |
| 2002 | 3.03% | 1.68% | 0.68x | 2.64x | CN¥-43.17 Million |
| 2003 | 0.92% | 0.51% | 0.68x | 2.67x | CN¥-56.69 Million |
| 2004 | 1.99% | 0.92% | 0.75x | 2.87x | CN¥-51.29 Million |
| 2005 | 11.27% | 4.33% | 0.85x | 3.05x | CN¥9.18 Million |
| 2006 | 7.59% | 2.66% | 0.87x | 3.28x | CN¥-18.60 Million |
| 2007 | 6.51% | 2.56% | 0.78x | 3.27x | CN¥-30.30 Million |
| 2008 | 54.05% | 25.86% | 1.15x | 1.81x | CN¥792.68 Million |
| 2009 | 42.60% | 29.01% | 1.08x | 1.36x | CN¥928.84 Million |
| 2010 | 29.68% | 25.11% | 0.98x | 1.20x | CN¥758.99 Million |
| 2011 | 23.06% | 20.98% | 0.93x | 1.18x | CN¥573.39 Million |
| 2012 | 13.72% | 16.12% | 0.75x | 1.14x | CN¥229.90 Million |
| 2013 | 7.00% | 9.16% | 0.65x | 1.17x | CN¥-193.72 Million |
| 2014 | 2.60% | 3.51% | 0.61x | 1.20x | CN¥-484.09 Million |
| 2015 | 2.45% | 3.60% | 0.55x | 1.25x | CN¥-497.73 Million |
| 2016 | 6.45% | 8.53% | 0.60x | 1.26x | CN¥-247.72 Million |
| 2017 | 3.47% | 4.45% | 0.58x | 1.34x | CN¥-475.78 Million |
| 2018 | 4.77% | 5.32% | 0.68x | 1.31x | CN¥-400.13 Million |
| 2019 | 4.36% | 4.87% | 0.68x | 1.32x | CN¥-443.31 Million |
| 2020 | 9.35% | 9.79% | 0.70x | 1.37x | CN¥-50.06 Million |
| 2021 | 11.91% | 11.45% | 0.73x | 1.43x | CN¥167.41 Million |
| 2022 | 5.83% | 6.65% | 0.65x | 1.34x | CN¥-386.42 Million |
| 2023 | 4.46% | 5.51% | 0.61x | 1.33x | CN¥-533.43 Million |
| 2024 | 10.90% | 12.38% | 0.68x | 1.30x | CN¥95.70 Million |
| 2025 | 7.98% | 9.83% | 0.63x | 1.29x | CN¥-220.96 Million |
Industry Comparison
This section compares Zhejiang Medicine Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,877,324,223
- Average return on equity (ROE) among peers: 8.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Medicine Co Ltd (600216) | CN¥11.37 Billion | 12.22% | 0.25x | $1.79 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.78 Billion | 1.33% | 4.40x | $589.07 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.56 Billion | 7.90% | 1.45x | $422.95 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $2.46 Billion | 15.95% | 0.27x | $4.31 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.17 Billion | 10.59% | 0.88x | $2.30 Billion |
| Wedge Industrial Co Ltd (000534) | $1.41 Billion | 5.42% | 0.68x | $1.73 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $32.60 Million | 12.25% | 0.82x | $13.40 Billion |
| Hainan Haiyao Co Ltd (000566) | $2.54 Billion | 7.70% | 0.92x | $945.43 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $380.02 Million | 7.98% | 0.67x | $320.64 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $3.92 Billion | 4.44% | 2.20x | $1.01 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $23.53 Billion | 7.26% | 0.16x | $3.11 Billion |
About Zhejiang Medicine Co Ltd
Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and pharmaceuticals products in China and internationally. The company offers synthetic vitamin E, vitamin A, natural vitamin E, ß-carotene, canthaxanthin, vancomycin hydrochloride, teicoplanin, and daptomycin. It also provides fat-soluble vitamins, quinolone antibiotics, anti-drug-resistant antibiotics, and other products, as well… Read more